ARTICLE | Deals
Arch, Monograph-backed HI-Bio builds pipeline with MorphoSys deal
German biotech offloads rights to pair of programs with potential in immunology, tightens focus on oncology
June 14, 2022 9:54 PM UTC
By offloading two clinical programs to a start-up backed by Arch and Monograph, MorphoSys will conserve resources for its own oncology pipeline while taking an equity stake in the immunology-focused newco that will advance the out-licensed programs.
Late Tuesday, MorphoSys AG (Xetra:MOR; NASDAQ:MOR) said it will grant Human Immunology Biosciences Inc. rights in most global territories to CD38-blocking antibody felzartamab and anti-C5AR1 antibody MOR210...